Financials ALK-Abelló A/S

Equities

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:59 2024-04-26 am EDT 5-day change 1st Jan Change
130 DKK +4.50% Intraday chart for ALK-Abelló A/S +3.50% +28.46%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,801 27,291 37,650 21,222 22,384 28,755 - -
Enterprise Value (EV) 1 18,475 27,697 37,922 21,430 22,374 28,390 27,716 26,609
P/E ratio -356 x 1,101 x 173 x 63.6 x 46 x 36.9 x 27.4 x 22.6 x
Yield - - - - - - - -
Capitalization / Revenue 5.44 x 7.82 x 9.61 x 4.7 x 4.64 x 5.37 x 4.87 x 4.44 x
EV / Revenue 5.64 x 7.93 x 9.68 x 4.75 x 4.64 x 5.31 x 4.69 x 4.1 x
EV / EBITDA 76.7 x 70.1 x 71 x 30.3 x 24.6 x 22.3 x 16.5 x 13.8 x
EV / FCF -739 x 495 x 188 x 330 x 76.6 x 83.3 x 32.4 x 24.8 x
FCF Yield -0.14% 0.2% 0.53% 0.3% 1.31% 1.2% 3.08% 4.03%
Price to Book 5.74 x 8.83 x 11 x 5.34 x 5.06 x 5.54 x 4.6 x 3.83 x
Nbr of stocks (in thousands) 217,745 218,327 219,534 220,946 221,189 221,189 - -
Reference price 2 81.75 125.0 171.5 96.05 101.2 130.0 130.0 130.0
Announcement Date 2/5/20 2/10/21 2/8/22 2/3/23 2/8/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,274 3,491 3,916 4,511 4,824 5,350 5,907 6,483
EBITDA 1 241 395 534 708 911 1,274 1,679 1,930
EBIT 1 -14 150 292 470 666 1,005 1,391 1,648
Operating Margin -0.43% 4.3% 7.46% 10.42% 13.81% 18.79% 23.55% 25.42%
Earnings before Tax (EBT) 1 -31 101 279 447 647 994.2 1,379 1,647
Net income 1 -50 25 219 335 486 759.9 1,058 1,275
Net margin -1.53% 0.72% 5.59% 7.43% 10.07% 14.2% 17.91% 19.67%
EPS 2 -0.2295 0.1135 0.9900 1.510 2.200 3.522 4.753 5.741
Free Cash Flow 1 -25 56 202 65 292 341 855 1,073
FCF margin -0.76% 1.6% 5.16% 1.44% 6.05% 6.37% 14.47% 16.56%
FCF Conversion (EBITDA) - 14.18% 37.83% 9.18% 32.05% 26.77% 50.92% 55.61%
FCF Conversion (Net income) - 224% 92.24% 19.4% 60.08% 44.87% 80.84% 84.18%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/5/20 2/10/21 2/8/22 2/3/23 2/8/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 928 1,099 1,155 1,045 1,062 1,249 1,234 1,135 1,110 1,345 1,353 1,246 1,237 1,516
EBITDA 1 124 136 272 107 128 201 288 157 208 258 359.5 235 289 405.5
EBIT 1 55 79 215 49 68 138 228 97 147 194 289 163.5 218.5 335
Operating Margin 5.93% 7.19% 18.61% 4.69% 6.4% 11.05% 18.48% 8.55% 13.24% 14.42% 21.36% 13.12% 17.66% 22.09%
Earnings before Tax (EBT) 1 54 74 217 56 70 104 217 89 155 186 291 147 206 317
Net income 1 37 76 163 42 52 78 163 66 117 140 214.5 120 160.9 249.5
Net margin 3.99% 6.92% 14.11% 4.02% 4.9% 6.24% 13.21% 5.81% 10.54% 10.41% 15.85% 9.63% 13.01% 16.45%
EPS 2 0.1700 0.3450 0.7400 0.1900 0.2300 0.3500 0.7000 0.3000 0.5000 0.7000 0.9650 0.5350 0.7200 1.130
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/11/21 2/8/22 5/12/22 8/11/22 11/10/22 2/3/23 5/9/23 8/24/23 11/15/23 2/8/24 - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 674 406 272 208 - - - -
Net Cash position 1 - - - - 10 364 1,039 2,146
Leverage (Debt/EBITDA) 2.797 x 1.028 x 0.5094 x 0.2938 x - - - -
Free Cash Flow 1 -25 56 202 65 292 341 855 1,073
ROE (net income / shareholders' equity) -1.6% 0.8% 6.6% 9% 11.5% 15.8% 18.4% 18.2%
ROA (Net income/ Total Assets) -0.97% 0.45% 3.84% 5.52% 7.46% 10.8% 13.3% 13.7%
Assets 1 5,181 5,529 5,696 6,069 6,517 7,044 7,965 9,291
Book Value Per Share 2 14.30 14.20 15.60 18.00 20.00 23.50 28.30 33.90
Cash Flow per Share 2 0.6100 1.380 2.140 1.900 3.000 3.500 5.500 6.100
Capex 1 147 196 263 353 379 380 377 402
Capex / Sales 4.49% 5.61% 6.72% 7.83% 7.86% 7.1% 6.39% 6.2%
Announcement Date 2/5/20 2/10/21 2/8/22 2/3/23 2/8/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
130 DKK
Average target price
132.8 DKK
Spread / Average Target
+2.12%
Consensus
  1. Stock Market
  2. Equities
  3. ALK B Stock
  4. Financials ALK-Abelló A/S